Neoplasms

Digestive System Diseases

All Conditions

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Antineoplastic Agents

All Drugs and Chemicals

Panitumumab

Antineoplastic Agents, Immunological

Participants with wild-type RAS metastatic colorectal cancer who were receiving panitumumab in combination with chemotherapy.

Participants receiving panitumumab in combination with chemotherapy as prescribed by the treating physician prior to enrollment in this study and according to routine clinical practice for patients with wild-type RAS metastatic colorectal cancer.

Panitumumab + Chemotherapy

The primary objective was to describe the pattern of use of panitumumab (Vectibix®) in combination with chemotherapy in patients with wild-type rat sarcoma viral oncogene homolog (RAS) metastatic colorectal cancer (mCRC): as first-line treatment in combination with FOLFOX or FOLFIRI or second-line treatment in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).

Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients

Prospective Observational Cohort Study to Describe the Use of Vectibix® in Combination With Chemotherapy in Routine Clinical Practice for Patients With Wild-type RAS Metastatic Colorectal Cancer

Duration of exposure is the time from the first to the last panitumumab infusion

Duration of exposure is the time from the first date to the last date of chemotherapy administration.

Participants may have had more than one type of hospital visit.

Participants may have had more than one hospital visit and/or reason for a hospital visit.

Tumor response was assessed by the investigator using standard radiological imaging. Overall response is defined as a best tumor response of complete response or partial response according to Response Evaluation Criteria In Solid Tumours (RECIST).

Resectability denotes whether a participant became resectable during the study.

Participants may have received more than one type of anti-cancer treatment that was initiated after panitumumab discontinuation.

Amgen

Only adverse reactions considered by the investigator to be related to panitumumab together with product complaints and other safety findings were collected in this observational study.

Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.

Participants with metastatic colorectal cancer (mCRC) with tumor expressing wild-type RAS who received panitumumab in combination with FOLFOX as first-line treatment (FLFAS).

Panitumumab + FOLFOX First-line

Participants with mCRC with tumor expressing wild-type RAS who received panitumumab in combination with FOLFIRI as second-line treatment and received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan) (SLFAS).

Panitumumab + FOLFIRI Second-line

Participants with mCRC with tumor expressing wild-type RAS who received panitumumab in combination with FOLFIRI as first-line treatment (FLFFAS).

Panitumumab + FOLFIRI First-line

Total

Age, Continuous

Age, Customized

Sex: Female, Male

A scale to assess a patient's disease status. 0 = Fully active, able to carry out all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out work of a light nature; 2 = Ambulatory and capable of all self-care, unable to carry out any work activities. Up and about \> 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; 4 = Completely disabled, confined to bed or chair; 5 = Dead.

Eastern Cooperative Oncology Group (ECOG) Performance Status

Primary Colorectal Cancer Type

Synchronous colorectal neoplasias are defined as 2 or more primary tumors identified in the same patient and at the same time.

Metachronous refers to lesions that appear after diagnosis of the primary lesion.

Metastatic Colorectal Cancer Status

Liver

Lung

Other

Metastatic Disease Lesion Sites

Study Director

Total Number of Panitumumab Infusions

Cumulative Dose of Panitumumab

Maximum Dose of Panitumumab

Duration of Panitumumab Exposure

Mean Interval Between Panitumumab Infusions

Percentage of Participants With at Least One Panitumumab Dose Reduction

Percentage of Participants With at Least One Panitumumab Dose Delay

Participants who discontinued panitumumab while on study

Reasons for Discontinuation of Panitumumab

Duration of Exposure of All Concomitant Chemotherapy

Percentage of Participants With at Least One Concomitant Chemotherapy Dose Reduction

Percentage of Participants With at Least One Concomitant Chemotherapy Dose Delay

Number of Participants With at Least One Hospitalization

Outpatient

Inpatient

Emergency room

Day case

Participants with at least one hospital visit

Types of Hospital Visit

Duration of Hospital Stay

mCRC related

Treatment-related

mCRC and treatment related

Participants with at least one hospitalization

Reasons for Hospitalization

Participants with tumor response data post-baseline

Percentage of Participants With an Overall Response

Number of Participants With Resectability

Number of Participants With Anti-cancer Treatment After Panitumumab Discontinuation

Chemotherapy

Radiotherapy

Targeted biologics

Other small molecules

Participants who reported use of anti-cancer treatment after discontinuation of panitumumab

Spots Global Cancer Trial Database for Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial